Treatment of experimental autoimmune myasthenia gravis rats with FTY720 and its effect on Th1/Th2 cells

Huang,Jiankang; Zhang,Ting; Wang,Hongmei; Zhao,Yuwu

doi:10.3892/mmr.2018.8768

Treatment of experimental autoimmune myasthenia gravis rats with FTY720 and its effect on Th1/Th2 cells

Authors:
- Jiankang Huang
- Ting Zhang
- Hongmei Wang
- Yuwu Zhao
View Affiliations

Affiliations: Department of Neurology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: March 16, 2018 https://doi.org/10.3892/mmr.2018.8768
Pages: 7409-7414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myasthenia gravis (MG) is an autoimmune neurological disease that is characterized by the expression of anti-acetylcholine receptor (AChR) antibodies. The immune response at AChRs of neuromuscular junction is disrupted in patients with MG, which manifests as skeletal muscle fatigue and is aggravated following periods of activity and alleviated following rest. Although a novel immune suppressant FTY720 drug, which exhibits strong immune suppression efficacy and minor adverse effects, is available, its role and mechanism in MG have not been elucidated. The aim of this study was to investigate the role of FTY720 in MG. A total of 60 healthy female Lewis rats were randomly assigned into 4 groups: Control group, Model group of experimental autoimmune myasthenia gravis (EAMG), 0.5 mg/kg FTY720-treatment EAMG group and 1.0 mg/kg FTY720‑treatment EAMG group. Body weight and symptoms were examined; Lennon score was used to evaluate improvement of clinical symptoms. Reverse transcription‑quantitative polymerase chain reaction and ELISA were used to test the mRNA and protein expression levels, respectively, of the helper T (Th)1 and Th2 cell cytokines, including interleukin (IL)‑2, interferon (IFN)‑γ, IL‑4 and IL‑6 in thymus tissue and serum. FTY720 treatment improved rat MG symptoms, increased body weight and decreased Lennon score. FTY720 treatments also reduced tissue and serum levels of IL‑2, IFN‑γ and IL‑6, but not IL‑4 expression levels. FTY720 suppressed the inflammatory response and improved EAMG symptoms by inhibiting the secretion of inflammatory factors.

View Figures

View References

1	Lizarraga AA, Lizarraga KJ and Benatar M: Getting rid of weakness in the ICU: An updated approach to the acute management of myasthenia gravis and guillain-barré syndrome. Semin Neurol. 36:615–624. 2016. View Article : Google Scholar : PubMed/NCBI
2	Sonkar KK, Bhoi SK, Dubey D, Kalita J and Misra UK: Direct and indirect cost of myasthenia gravis: A prospective study from a tertiary care teaching hospital in India. J Clin Neurosci. 38:114–117. 2016. View Article : Google Scholar : PubMed/NCBI
3	Beck G, Yabumoto T, Baba K, Sasaki T, Higuchi O, Matsuo H and Mochizuki H: Double seronegative myasthenia gravis with anti-LRP4 antibodies presenting with dropped head and acute respiratory insufficiency. Intern Med. 55:3361–3363. 2016. View Article : Google Scholar : PubMed/NCBI
4	Xin Y, Cai H, Lu T, Zhang Y, Yang Y and Cui Y: miR-20b Inhibits T Cell Proliferation and Activation via NFAT signaling pathway in thymoma-associated myasthenia gravis. Biomed Res Int. 2016:95957182016. View Article : Google Scholar : PubMed/NCBI
5	Lee HE, Kim YH, Kim SM and Shin HY: Clinical significance of repetitive compound muscle action potentials in patients with myasthenia gravis: A predictor for cholinergic side effects of acetylcholinesterase inhibitors. J Clin Neurol. 12:482–488. 2016. View Article : Google Scholar : PubMed/NCBI
6	Gung Y, Zhang H, Li S and Wang Y: Sternotomy versus video-assisted thoracoscopic surgery for thymectomy of myasthenia gravis patients: A meta-analysis. Asian J Endosc Surg. 9:285–294. 2016. View Article : Google Scholar : PubMed/NCBI
7	Meng QF, Zhang Z, Wang YJ, Chen W, Li FF, Yue LT, Zhang CJ, Li H, Zhang M, Wang CC, et al: Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells. J Neuroimmunol. 298:138–145. 2016. View Article : Google Scholar : PubMed/NCBI
8	Zhang H, Geng Y, Zheng Y and Wang Y: A case of anterior mediastinitis and bilateral multiple lung abscesses occurring after trans-subxiphoid video-assisted thoracoscopic extended thymectomy for thymoma with myasthenia gravis. J Thorac Dis. 8:E970–E973. 2016. View Article : Google Scholar : PubMed/NCBI
9	Nikolic AV, Bojic SD, RakocevicStojanovic VM, Basta IZ and Lavrnic DV: Electrophysiological findings in patients with low density lipoprotein receptor related protein 4 positive myasthenia gravis. Eur J Neurol. 23:1635–1641. 2016. View Article : Google Scholar : PubMed/NCBI
10	Vargas-Rojas MI, Solleiro-Villavicencio H and Soto-Vega E: Th1, Th2, Th17 and Treg levels in umbilical cord blood in preeclampsia. J Matern Fetal Neonatal Med. 29:1642–1645. 2016. View Article : Google Scholar : PubMed/NCBI
11	Tian T, Yu S, Liu L, Xue F, Yuan C, Wang M, Ji C and Ma D: The profile of T helper subsets in bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations. PLoS One. 10:e01317612015. View Article : Google Scholar : PubMed/NCBI
12	Kornete M, Mason ES, Girouard J, Lafferty EI, Qureshi S and Piccirillo CA: Th1-Like ICOS⁺ Foxp3⁺T_reg cells preferentially express CXCR3 and home to β-islets during pre-diabetes in BDC2.5 NOD Mice. PLoS One. 10:e01263112015. View Article : Google Scholar : PubMed/NCBI
13	Wang J, Cao H, Wang H, Yin G, Du J, Xia F, Lu J and Xiang M: Multiple mechanisms involved in diabetes protection by lipopolysaccharide in non-obese diabetic mice. Toxicol Appl Pharmacol. 285:149–158. 2015. View Article : Google Scholar : PubMed/NCBI
14	Takahashi H, Noto YI, Makita N, Kushimura-Okada Y, Ishii R, Tanaka A, Ohara T, Nakane S, Higuchi O, Nakagawa M and Mizuno T: Myasthenic symptoms in anti-low-density lipoprotein receptor-related protein 4 antibody-seropositive amyotrophic lateral sclerosis: Two case reports. BMC Neurol. 16:2292016. View Article : Google Scholar : PubMed/NCBI
15	Rahman MM, Prunte L, Lebender LF, Patel BS, Gelissen I, Hansbro PM, Morris JC, Clark AR, Verrills NM and Ammit AJ: The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells. Sci Rep. 6:372972016. View Article : Google Scholar : PubMed/NCBI
16	Breart B and Bousso P: S1P₁ downregulation tailors CD8⁺ T-cell residence time in lymph nodes to the strength of the antigenic stimulation. Eur J Immunol. 46:2730–2736. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kaminski HJ, Himuro K, Alshaikh J, Gong B, Cheng G and Kusner LL: Differential RNA expression profile of skeletal muscle induced by experimental autoimmune myasthenia gravis in rats. Front Physiol. 7:5242016. View Article : Google Scholar : PubMed/NCBI
18	Lennon VA, Lindstrom JM and Seybold ME: Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med. 141:1365–1375. 1975. View Article : Google Scholar : PubMed/NCBI
19	Meng X, Liu Y, Wang H, Liu L and Gong H: Effcacy of tripterygium glycosides on experimentalautoimmune myasthenia gravis in rats. Int J Clin Exp Med. 10:12235–12239. 2017.
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Anand G, Vasanthakumar R, Mohan V, Babu S and Aravindhan V: Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy (CURES-134). Int J Clin Exp Pathol. 7:8008–8015. 2014.PubMed/NCBI
22	Dalakas MC: Future perspectives in target-specific immunotherapies of myasthenia gravis. Ther Adv Neurol Disord. 8:316–327. 2015. View Article : Google Scholar : PubMed/NCBI
23	Luo J and Lindstrom J: AChR-specific immunosuppressive therapy of myasthenia gravis. Biochem Pharmacol. 97:609–619. 2015. View Article : Google Scholar : PubMed/NCBI
24	Yu Y, Cao F, Ran Q and Sun X: Regulatory T cells exhibit neuroprotective effect in a mouse model of traumatic brain injury. Mol Med Rep. 14:5556–5566. 2016. View Article : Google Scholar : PubMed/NCBI
25	Uzawa A, Kanai T, Kawaguchi N, Oda F, Himuro K and Kuwabara S: Changes in inflammatory cytokine networks in myasthenia gravis. Sci Rep. 6:258862016. View Article : Google Scholar : PubMed/NCBI
26	Li H, Wang CC, Zhang M, Li XL, Zhang P, Yue LT, Miao S, Wang S, Liu Y, Li YB and Duan RS: Statin-modified dendritic cells regulate humoral immunity in experimental autoimmune myasthenia gravis. Mol Cell Neurosci. 68:284–292. 2015. View Article : Google Scholar : PubMed/NCBI
27	Fan X, Lin C, Han J, Jiang X, Zhu J and Jin T: Follicular helper CD4⁺ T cells in human neuroautoimmune diseases and their animal models. Mediators Inflamm. 2015:6389682015. View Article : Google Scholar : PubMed/NCBI
28	Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, Gulsen-Parman Y, Tzartos S, Marx A, Tuzun E, et al: Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK. PLoS One. 10:e01235462015. View Article : Google Scholar : PubMed/NCBI